AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00871065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Description: 20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
Study NCT00306137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trasylol (Aprotinin, BAYA0128)
Description: Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.~Subjects will be stratified into one of the 4 following strata:~* Stratum 1: complete primary pneumonectomy~* Stratum II: decortication or completion pneumonectomy~* Stratum III: esophagectomy by transhiatal approach~* Stratum IV: esophagectomy by transthoracic approach
Study NCT00306137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
Study NCT01293318 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00891501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
Study NCT00891501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cell implantation
Description: The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
Study NCT01393626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets twice daily
Study NCT01393626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: oral tablets twice daily
Study NCT00627458 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix Hexa
Description: Vaccine administered as a booster dose at 16-20 months of age
Study NCT00627458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix Hexa
Description: Vaccine administered as a booster dose at 16-20 months of age
Study NCT03447054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined TDCS active and ICT active
Description: Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days
Study NCT03447054 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Combined TDCS sham and ICT active
Description: Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days
Study NCT03447054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined TDCS active and ICT inactive
Description: Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days
Study NCT03447054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Sham TDCS and inactive ICT
Description: Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days
Study NCT01825616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2 mushroom powder
Description: Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.
Study NCT01825616 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mushroom powder without vitamin D2
Study NCT00601276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprorelin
Description: Subcutaneous injection, 3.75 mg every 4 weeks
Study NCT00601276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproterone acetate
Description: 2.0 mg/kg/day, tablet, per os
Study NCT00424931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-17216498
Description: 50mg one time
Study NCT00424931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-17216498
Description: 10mg one time
Study NCT00424931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 200 mg X 2
Study NCT00916292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF-1 141
Description: Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
Study NCT00916292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FGF-1 141
Description: Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
Study NCT02388607 — intervention group
Intervention type: OTHER
Intervention: measurements
Description: performance measurements
Study NCT03086980 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Self Transcending Meditation
Description: Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
Study NCT03086980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Usual Care will be provided.
Study NCT04008082 — intervention group
Intervention type: DRUG
Intervention: Lenvatinib
Description: Lenvatinib capsule.
Study NCT04831931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program Applied by Telerehabilitation
Description: Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups.
Study NCT04831931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program Applied by Telerehabilitation
Description: Patients will be evaluated 3 times for 4 weeks throughout the study; before the study commences, at the end of 2th and 4th week~Exercises will be planned to last for 15 minutes a day, and will be progressed and changed weekly throughout the study period. To the exercise program; It will be created as a progressive program by including stretching, normal range of motion movements, neck, core and scapular stabilization and strengthening exercises and the same program will be given to both groups.
Study NCT02397174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mediterranean diet, restricted calorie
Description: 50 pcos women will be assigned to hypocaloric mediterranean diet for 6 months
Study NCT02397174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypocaloric diet, restricted calorie
Description: 50 pcos women will be assigned to standardized hypocaloric diet for 6 months
Study NCT04170049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Stimulative Activitiy ( proprioceptive intervention, music intervention )
Description: Music intervention: Listening to soft music was found to be an effective method of relaxation, as indicated by a shift of the autonomic balance toward parasympathetic activity. Participants listen to preferred soft music for 30 minutes before sleeping. Proprioceptive intervention: The proprioceptive intervention can activate the parasympathetic nervous system through pathways of the central nervous system, providing calming effects that significantly reduce anxiety, hyperactivity and agitation in various populations.Participants do 10-minute joint compression exercise three times per day by themselves.
Study NCT03305783 — intervention group
Intervention type: PROCEDURE
Intervention: cholecystectomy
Description: elective cholecystectomy performed due to gallstones, cholecystitis or other non-malignant conditions and therefore done regardless of the protocol of this study.
Study NCT03899506 — intervention group
Intervention type: DRUG
Intervention: Olanzapine
Description: Patients receiving Olanzapine per the ED protocol
Study NCT03899506 — intervention group
Intervention type: DRUG
Intervention: Midazolam
Description: Patients receiving Midazolam per the ED protocol
Study NCT02296047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: physiological saline
Study NCT02296047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Description: 80 µg inhalation once
Study NCT02296047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: 400 µg inhalation once
Study NCT01220037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adhere to a specific standardized diet for 4 days
Description: 24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.
Study NCT04049695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This intervention is based on Control Theory and Social Cognitive Theory and includes: 1) weekly emails with tips and tools to set personalized exercise goals and to increase exercise; 2) Health coaching phone sessions; 3) wrist worn monitor such as a Fitbit to track activity
Study NCT04049695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This intervention includes: 1) weekly emails with tips and tools to support health and wellness such as brain health, stress management, nutrition; 2) Health coaching phone sessions
Study NCT02590978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Description: Cholecystectomy + intraoperative cholangiography within the first 72 hours of admission.
Study NCT02590978 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control (Delayed cholecystectomy)
Description: Standard care arm. Cholecystectomy + intraoperative cholangiography is delayed once complete resolution of abdominal tenderness, oral feeding and trending down in pancreatic laboratory is achieved
Study NCT04078659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Description: Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
Study NCT04078659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate infusion
Description: Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
Study NCT04078659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
Study NCT04078659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
Study NCT04078659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients will receive propofol in a dose of 1-2 mg /kg
Study NCT00520065 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enteral nutritional formula
Description: Meal glucose tolerance test
Study NCT04203368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine
Description: patients received IV adenosine 6 mg bolus then wait 2 minutes, if it failed to return to sinus rhythm then another 12 mg IV bolus of adenosine was administered, if supraventricular tachycardia persisted then the patient was shifted to verapamil.
Study NCT00520065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes specific enteral product
Description: Meal Glucose tolerance test
Study NCT03034980 — intervention group
Intervention type: OTHER
Intervention: Training intensity (workload) during ergospirometry
Description: The reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.
Study NCT02441738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid Ablation
Description: The procedure will be performed following standard of care guidelines.
Study NCT02441738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Ablation
Description: The procedure will be performed following standard of care guidelines.
Study NCT00373230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
Study NCT00373230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telemedicine
Description: One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
Study NCT02894645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Oral
Study NCT02894645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Oral
Study NCT02894645 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: L-Asparaginase
Description: Intramuscular injection
Study NCT04203368 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: verapamil
Description: patients received IV verapamil 5mg bolus slowly over 2 minutes followed by a second IV bolus dose of 5 mg ,10 minutes after the initial dose in case of persistence of supraventricular tachycardia (SVT). If SVT persisted, the patient was shifted to adenosine
Study NCT00946010 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sampling and abdominal sonography
Description: 10cc blood sampling and abdominal sonography
Study NCT02447380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094
Description: AZD6094 600MG qd
Study NCT02447380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60 mg/m2
Study NCT04078659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atracurium
Description: Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
Study NCT04078659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
Study NCT01385683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran then dabigatran and clarithromycin
Description: D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
Study NCT01385683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin and dabigatran then dabigatran
Description: D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
Study NCT04035733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVA576
Description: BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.
Study NCT00913562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: one tablet rosuvastatin 10 mg per day for 12 weeks
Study NCT00913562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet a day for 12 weeks
Study NCT02536729 — intervention group
Intervention type: DRUG
Intervention: Oral Sodium Phosphate - Normal preparation
Study NCT02515552 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The Fibromyalgia Wellness Project
Description: Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
Study NCT03964090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDD-R
Description: Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4
Study NCT03964090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEDDI-R
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4
Study NCT03964090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: For Arm 1:Ibrutinib given on days -14 to day -1 prior to cycle 1;then given every 21 days for cycles 1-4 For Arm 2: Ibrutinib given on days -14 to day -1 prior to cycle 1; then on days 1-10 for cycles 1-4
Study NCT03964090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine on days 1 and day 5 of cycles 2-5 (all arms), as applicable
Study NCT03964090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Isavuconazole to begin at least 3 days prior to ibrutinib and continue throughout chemotherapy unless ibrutinib discontinued permanently
Study NCT03964090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate on days 1 and day 5 of cycles 2-5 (all arms), as applicable
Study NCT02208388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computed tomography perfusion guided treatment
Study NCT02536729 — intervention group
Intervention type: DRUG
Intervention: Oral sodium phosphate - Modified Preparation
Study NCT02208388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional flow reserve guided treatment
Study NCT00000135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSL-109
Description: 60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
Study NCT00000135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
Study NCT04479488 — intervention group
Intervention type: OTHER
Intervention: Hospital admission
Description: Usual care.
Study NCT04479488 — intervention group
Intervention type: OTHER
Intervention: Non-hospitalization procedures
Description: Usual care.
Study NCT03989037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP-01
Description: IBP-01: injection; strength: 150mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
Study NCT03989037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin: injection; strength: 440mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
Study NCT03989037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;
Study NCT03989037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;
Study NCT03989037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
Study NCT03989037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
Study NCT03078192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE-141, Hyperpolarized 129Xenon gas
Description: XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe
Study NCT03078192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon